Clinical Trials
35 trialsA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
COLIBRI-GI
UNICANCER
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Oncolytics Biotech
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
NAUTICALCRC
Pierre Fabre Medicament
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
RAMIRIS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
INAVO-CRC
Hoffmann-La Roche
RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
Intensified Chemotherapy in CRC After Resection of Liver Metastases
Institut du Cancer de Montpellier - Val d'Aurelle
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
AIO-KRK-0418
Charite University, Berlin, Germany
MINOTAUR
Debiopharm International SA
ParpVax2
Abramson Cancer Center at Penn Medicine
BEVANEC
Hospices Civils de Lyon
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
University of Alabama at Birmingham
DeFianCe
Leap Therapeutics, Inc.
TEDOPAM
GERCOR - Multidisciplinary Oncology Cooperative Group
SAMCO
Federation Francophone de Cancerologie Digestive
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Sun Yat-sen University
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
TheraOp